Vir Biotechnology (NASDAQ:VIR – Get Free Report) and Creative Medical Technology (NASDAQ:CELZ – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.
Volatility & Risk
Vir Biotechnology has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.
Institutional & Insider Ownership
65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Vir Biotechnology | -2,963.54% | -50.76% | -40.63% |
| Creative Medical Technology | N/A | -88.90% | -85.24% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Vir Biotechnology and Creative Medical Technology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vir Biotechnology | 1 | 0 | 7 | 0 | 2.75 |
| Creative Medical Technology | 1 | 1 | 0 | 0 | 1.50 |
Vir Biotechnology presently has a consensus target price of $17.00, indicating a potential upside of 183.33%. Given Vir Biotechnology’s stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Creative Medical Technology.
Earnings and Valuation
This table compares Vir Biotechnology and Creative Medical Technology”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vir Biotechnology | $74.21 million | 11.25 | -$521.96 million | ($3.61) | -1.66 |
| Creative Medical Technology | $10,000.00 | 510.84 | -$5.49 million | ($2.91) | -0.68 |
Creative Medical Technology has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Summary
Vir Biotechnology beats Creative Medical Technology on 8 of the 14 factors compared between the two stocks.
About Vir Biotechnology
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
